Claims for Patent: 5,807,833

Summary for Patent: 5,807,833

Title:	Hydroxyethyl starch and use thereof as an absorbable mechanical barrier and intracavity carrier device
Abstract:	Hydroxyethyl starch (HES) and use thereof in methods are provided for reducing or preventing of adhesion formation between tissue surfaces, e.g., organ surfaces, in body cavities following surgical procedures and for drug delivery. HES may be used as an absorbable mechanical barrier alone or in combination with one or more anti-adhesion formation compounds for application to injured areas of tissues, e.g., organs, situated in body cavities such as the peritoneal, pelvic, pleural cavity, central nervous system and interligamentous space. HES may also be used as an intracavity carrier device for delivery of pharmaceutically active agents.
Inventor(s):	Dizerega; Gere Stodder (Pasadena, CA)
Assignee:	University of Southern California (Los Angeles, CA)
Application Number:	08/482,235
Patent Claims:	1. A method for reducing or preventing formation of post-surgical adhesions between tissue surfaces in a body cavity of a host, comprising administering a composition comprising an effective anti-adhesion formation amount of hydroxyethyl starch to a host tissue surface following surgical activity for a period of time sufficient to permit tissue repair. 2. The method according to claim 1, wherein said tissue repair comprises re-epithelization. 3. The method according to claim 1, wherein said tissue repair comprises mesothelial repair. 4. The method according to claim 1, wherein said hydroxethyl starch comprises an amylopectin having hydroxyethyl groups which are substituted on a molar ratio ranging between about 0.1 and about 0.8 of a hydroxyethyl group per glucopyranose unit. 5. The method according to claim 4, wherein said hydroxyethyl starch comprises amylopectin monomers of molecular weights ranging between about 3.times.10.sup.4 and about 4.times.10.sup.6 daltons. 6. The method according to claim 5, wherein said monomers range between about 2.times.10.sup.5 and about 2.4.times.10.sup.6 daltons. 7. The method according to claim 1, wherein said hydroxyethyl starch comprises HES-1:10, HES-7-8:10 or HES-5:10. 8. The method according to claim 1, wherein said composition is administered with a physiologically acceptable vehicle. 9. The method according to claim 8, wherein said vehicle comprises sterile water, saline or aqueous buffer solutions containing alkali or alkaline earth metal carbonates, phosphates, bicarbonates, citrates, borates, acetates, succinates and tromethamine (TRIS). 10. The method according to claim 8, wherein said vehicle comprises saline, phosphate buffered saline, citrate buffer, and Ringers lactate solution. 11. The method according to claim 1, wherein said composition further comprises an effective amount of at least one pharmaceutically active agent. 12. The method according to claim 11, wherein said pharmaceutically active agent comprises an anti-adhesion formation agent, an antibiotic agent, an antihistaminic, an anti-inflammatory agent, antifungal agent, amoebocidal agent, trichomonacidal agent, or antiprotozoal agent, an antiviral agent, antineoplastic agent or anti-inflammatory corticosteroid. 13. The method according to claim 12, wherein said anti-adhesion formation agent comprises a lazaroid, a retinoid, quinacrine, manoalide or an analog thereof, a 5-lipoxygenase inhibitor, ketotifen or an analog thereof, dipyridamole or an analog thereof, a NSAID, or an anti-inflammatory corticosteroid. 14. The method according to claim 12, wherein said anti-inflammatory corticosteroid comprises betamethasone or dexamethasone. 15. A method for reducing or preventing formation of post-surgical adhesions between tissue surfaces in a body cavity of a host, comprising administering a composition consisting essentially of an effective anti-adhesion formation amount of hydroxyethyl starch and a physiologically acceptable vehicle to a host tissue surface for a period of time sufficient to permit tissue repair. 16. The method according to claim 15, wherein said tissue repair comprises re-epithelization. 17. The method according to claim 16, wherein said tissue repair comprises mesothelial repair. 18. The method according to claim 15, wherein said hydroxethyl starch comprises an amylopectin having hydroxyethyl groups which are substituted on a molar ratio ranging between about 0.1 and about 0.8 of a hydroxyethyl group per glucopyranose unit. 19. The method according to claim 18, wherein said hydroxyethyl starch comprises amylopectin monomers of molecular weights ranging between about 3.times.10.sup.4 and about 4.times.10.sup.6 daltons. 20. The method according to claim 19, wherein said monomers range between about 2.times.10.sup.5 and about 2.4.times.10.sup.6 daltons. 21. The method according to claim 15, wherein said hydroxyethyl starch comprises HES-1:10, HES-7-8:10 or HES-5:10. 22. The method according to claim 15, wherein said vehicle comprises sterile water, saline or aqueous buffer solutions containing alkali or alkaline earth metal carbonates, phosphates, bicarbonates, citrates, borates, acetates, succinates and tromethamine (TRIS). 23. The method according to claim 15, wherein said vehicle comprises saline, phosphate buffered saline, citrate buffer, and Ringers lactate solution. 24. The method according to claim 15 wherein said composition is administered to a tissue surface following surgical activity. 25. A method for reducing or preventing formation of post-surgical adhesions between tissue surfaces in a body cavity of a host, comprising administering a composition consisting essentially of an effective anti-adhesion formation amount of hydroxyethyl starch, at least one pharmaceutically active agent, and a physiologically acceptable vehicle to a host tissue surface for a period of time sufficient to permit tissue repair. 26. The method according to claim 25, wherein said tissue repair comprises re-epithelization. 27. The method according to claim 25, wherein said tissue repair comprises mesothelial repair. 28. The method according to claim 25, wherein said hydroxethyl starch comprises an amylopectin having hydroxethyl groups which are substituted on a molar ratio ranging between about 0.1 and about 0.8 of a hydroxethyl group per glucopyranose unit. 29. The method according to claim 28, wherein said hydroxyethyl starch comprises amylopectin monomers of molecular weights ranging between about 3.times.10.sup.4 and about 4.times.10.sup.6 daltons. 30. The method according to claim 29, wherein said monomers range between about 2.times.10.sup.5 and about 2.4.times.10.sup.6 daltons. 31. The method according to claim 25, wherein said hydroxyethyl starch comprises HES-1:10, HES-7-8:10 or HES-5:10. 32. The method according to claim 25, wherein said vehicle comprises sterile water, saline or aqueous buffer solutions containing alkali or alkaline earth metal carbonates, phosphates, bicarbonates, citrates, borates, acetates, succinates and tromethamine (TRIS). 33. The method according to claim 25, wherein said vehicle comprises saline, phosphate buffered saline, citrate buffer, and Ringers lactate solution. 34. The method according to claim 25, wherein said pharmaceutically active agent comprises an anti-adhesion formation agent, an antibiotic agent, an antihistaminic, an anti-inflammatory agent, antifungal agent, amoebocidal agent, trichomonacidal agent, antiprotozoal agent, an antiviral agent, antineoplastic agent or anti-inflammatory corticosteroid. 35. The method according to claim 34, wherein said anti-adhesion formation agent comprises a lazaroid, a retinoid, quinacrine, manoalide or an analog thereof, a 5-lipoxygenase inhibitor, ketotifen or an analog thereof, dipyridamole or an analog thereof, a NSAID, or an anti-inflammatory corticosteroid. 36. The method according to claim 34, wherein said anti-inflammatory corticosteroid comprises betamethasone or dexamethasone. 37. The method according to claim 25 wherein said composition is administered to a tissue surface following surgical activity.

Details for Patent 5,807,833

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2039-09-23